Renal injury – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 10:53:40 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Renal injury – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Ilofotase Alfa to Prevent Kidney Damage in Patients Undergoing Open Heart Surgery https://clinicaltrials.eu/trial/study-on-ilofotase-alfa-to-prevent-kidney-damage-in-patients-undergoing-open-heart-surgery/ Wed, 29 Apr 2026 14:25:47 +0000 https://clinicaltrials.eu/trial/study-on-ilofotase-alfa-to-prevent-kidney-damage-in-patients-undergoing-open-heart-surgery/ This clinical trial is focused on patients who are at risk of developing renal damage after undergoing open heart surgery. The study is investigating a treatment called Ilofotase alfa, which is given as a concentrate for solution for infusion, meaning it is administered directly into the bloodstream through a vein. The purpose of the study is to evaluate how effective and safe Ilofotase alfa is in protecting the kidneys during and after heart surgery.

Participants in the trial will be randomly assigned to receive either Ilofotase alfa or a placebo, which is a substance with no active medication. The trial is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased. The study will monitor the participants’ kidney function by measuring levels of a substance called serum creatinine, which is a marker of kidney health, before and after the surgery.

Throughout the study, the safety of the participants will be closely monitored, and any side effects or adverse events will be recorded. The trial will also collect information on how the body processes Ilofotase alfa, known as pharmacokinetics. The study is expected to continue until 2025, with the aim of providing valuable insights into the potential benefits of Ilofotase alfa for patients undergoing heart surgery.

]]>